Business
Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
BOCA RATON, FLA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a biotech company focused on advancing cancer treatments, today announced that it has entered into definitive agreements in a registered direct offering with accredited investors for the purchase and sale of approximately $4.3 million of shares of Common Stock and pre-funded and investor warrants at a price of $4.09 per Common Unit. The entire transaction has been priced at the m
About this update from Lixte Biotechnology Holdings, Inc.
[{"type":"image","alt":"Lixte Biotechnology Holdings, Inc.","displaySize":"","headline":null,"caption":"Lixte Biotechnology Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":275,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/9518732e3aaf23fc68ee2aaea1795fc6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FmV0Y7aYPvvleZjVNFp7LQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9518732e3aaf23fc68ee2aaea1795fc6","width":275,"height":120}},"lazy":false},{"type":"text","content":"BOCA RATON, FLA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a biotech company focused on advancing cancer treatments, today announced that it has entered into definitive agreements in a registered direct offering with accredited investors for the purchase and sale of approximately $4.3 million of shares of Common Stock and pre-funded and investor warrants at a price of $4.09 per Common Unit. The entire transaction has been priced at the market under Nasdaq rules.","length":525,"tagName":"p"},{"type":"text","content":"The offering consisted of the sale of 1,051,342 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) one (1) Common Warrant to purchase one (1) share of Common Stock per warrant at an exercise price of $3.96. The public offering price per Common Unit is $4.09 (or $4.08999 for each Pre-Funded Unit, which is equal to the public offering price per Common Unit to be sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Unit sold in the offering, the number of Common Units in the offering will be decreased on a one-for-one basis. The initial exercise price of each Common Warrant is $3.96 per share of Common Stock. The Common Warrants are exercisable immediately and expire 60 months after the initial issuance date.","length":955,"tagName":"p"},{"type":"text","content":"Aggregate gross proceeds to the Company are expected to be approximately $4.3 million. The transaction is expected to close on or about December 19, 2025, subject to the satisfaction of customary closing conditions. Th...